Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides-Reference-Cited by-同舟云学术

Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides

Published:2013-04 Issue:4 Volume:5 Page:427-433
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Pileri Alessandro¹,Delfino Chiara²,Grandi Vieri²,Pimpinelli Nicola²

Affiliation:

1. Dermatology, Department of Specialised, Experimental & Diagnostic Medicine, University of Bologna, Italy.

2. Department of Surgery & Translational Medicine, Division of Dermatology, University of Florence Medical School, Florence, Italy

Abstract

Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphoid neoplasms. The incidence of CTCLs has risen over the last three decades. The most common CTCLs are mycosis fungoides and Sèzary syndrome. Therapies for CTCLs are various and range from skin-directed therapy to chemotherapy. Retinoids have been used in CTCL treatment since the 1980s with good results. Bexarotene is the first retinoid approved by the US FDA for CTCL therapy. Since then, numerous experiences of both its efficacy and mechanism of action have been reported. The aim of this paper is to review bexarotene action on CTCLs, as well as to highlight its immunological targets.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt.13.15

Reference46 articles.

1. SwerdlowSH, Campo E, Harris NLet al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO, Geneva, Switzerland,270–319 (2008).

2. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

3. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.

4. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

5. WHO-EORTC classification for cutaneous lymphomas

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group;Biochemical and Biophysical Research Communications;2024-11

2. Mycosis Fungoides Presenting With Multiple Tumors on the Face;Cureus;2024-05-27

3. Skin-directed therapy and biologic response modifiers in mycosis fungoides;Dermatology Reports;2024-05-07

4. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023;European Journal of Cancer;2023-12

5. Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo;Frontiers in Pharmacology;2023-05-31